Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice

References

• (NICE) NIfHaCE. Atrial fibrillation: managementClin Guideline2014148
   Google Scholar
• LipGYKamathSHartRGABC of antithrombotic therapy: anti-thrombotic therapy for cerebrovascular disordersBMJ200232573731161116312433770
   PubMedGoogle Scholar
• KirchhofPBenussiSKotechaD2016ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEur Heart J Cardiothorac Surg2016373828932962
   Google Scholar
• TurpieAGNew oral anticoagulants in atrial fibrillationEur Heart J200829215516518096568
   PubMed Web of Science ®Google Scholar
• SjogrenVGrzymala-LubanskiBRenlundHSafety and efficacy of well managed warfarin. A report from the Swedish quality register AuriculaThromb Haemost201511361370137725716771
   PubMed Web of Science ®Google Scholar
• AnsellJHirshJPollerLBusseyHJacobsonAHylekEThe pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyChest20041263 Suppl204S233S15383473
   PubMed Web of Science ®Google Scholar
• LooSYDell’AnielloSHuiartLRenouxCTrends in the prescription of novel oral anticoagulants in UK primary careBr J Clin Pharmacol20178392096210628390065
   PubMed Web of Science ®Google Scholar
• AbdulsattarYBhambriRNogidARivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor Xa inhibitorP T200934523824419561868
   PubMedGoogle Scholar
• KubitzaDBeckaMWensingGVoithBZuehlsdorfMSafety, pharmacodynamics, and pharmacokinetics of BAY 59–7939–an oral, direct Factor Xa inhibitor–after multiple dosing in healthy male subjectsEur J Clin Pharmacol2005611287388016328318
   PubMed Web of Science ®Google Scholar
• GulsethMPMichaudJNutescuEARivaroxaban: an oral direct inhibitor of factor XaAm J Health System Pharm200865161520152918693206
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMVoithBZuehlsdorfMWensingGSafety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitorClin Pharmacol Ther200578441242116198660
   PubMed Web of Science ®Google Scholar
• MueckWBorrisLCDahlOEPopulation pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacementThromb Haemost2008100345346118766262
   PubMed Web of Science ®Google Scholar
• MueckWStampfussJKubitzaDBeckaMClinical pharmacokinetic and pharmacodynamic profile of rivaroxabanClin Pharmacokinet201453111623999929
   PubMed Web of Science ®Google Scholar
• AbramsPJEmersonCRRivaroxaban: a novel, oral, direct factor Xa inhibitorPharmacotherapy200929216718119170587
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen ATCSGKSCWhy do we need observational studies of everyday patients in the real-life setting?Eur Heart J Suppl201517D2D8
   Web of Science ®Google Scholar
• BaiYDengHShantsilaALipGYRivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysisStroke201748497097628213573
   PubMed Web of Science ®Google Scholar
• CammAJAmarencoPHaasSXANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillationEur Heart J201637141145115326330425
   PubMed Web of Science ®Google Scholar
• Beyer-WestendorfJCammAJColemanCITamayoSRivaroxaban real-world evidence: validating safety and effectiveness in clinical practiceThromb Haemost2016116Suppl 2S13S2327623681
   PubMed Web of Science ®Google Scholar
• Koren-MoragNGoldbourtUTanneDRenal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular diseaseNeurology200667222422816864812
   PubMed Web of Science ®Google Scholar
• KawDMalhotraDPlatelet dysfunction and end-stage renal diseaseSemin Dial200619431732216893410
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMMueckWEffects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorBr J Clin Pharmacol201070570371221039764
   PubMed Web of Science ®Google Scholar
• YaoXShahNDSangaralinghamLRGershBJNoseworthyPANon-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunctionJ Am Coll Cardiol201769232779279028595692
   PubMed Web of Science ®Google Scholar
• HaasSBodeCNorrvingBTurpieAGPractical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and riskVasc Health Risk Manag20141010111424648742
   PubMedGoogle Scholar
• ZouRTaoJShiWMeta-analysis of safety and efficacy for direct oral anticoagulation treatment of non-valvular atrial fibrillation in relation to renal functionThromb Res2017160415029096154
   PubMed Web of Science ®Google Scholar
• YaoXTangriNGershBJRenal Outcomes in Anticoagulated Patients With Atrial FibrillationJ Am Coll Cardiol201770212621263229169468
   PubMed Web of Science ®Google Scholar
• Zoni-BerissoMLercariFCarazzaTDomenicucciSEpidemiology of atrial fibrillation: European perspectiveClin Epidemiol2014621322024966695
   PubMed Web of Science ®Google Scholar
• NgKHHartRGEikelboomJWAnticoagulation in patients aged ≥75 years with atrial fibrillation: role of novel oral anticoagulantsCardiol Ther20132213514925135392
   PubMedGoogle Scholar
• LauDHHuynhLTChewDPAstleyCMSomanASandersPPrognostic impact of types of atrial fibrillation in acute coronary syndromesAm J Cardiol2009104101317132319892044
   PubMed Web of Science ®Google Scholar
• Investigators AWGotAConnollySPogueJClopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trialLancet200636795261903191216765759
   PubMed Web of Science ®Google Scholar
• LeonMBBaimDSPopmaJJA clinical trial comparing three anti-thrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study InvestigatorsN Engl J Med199833923166516719834303
   PubMed Web of Science ®Google Scholar
• PaikinJSWrightDSCrowtherMAMehtaSREikelboomJWTriple antithrombotic therapy in patients with atrial fibrillation and coronary artery stentsCirculation2010121182067207020458022
   PubMed Web of Science ®Google Scholar
• Authors/Task Force membersWindeckerSKolhP2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Eur Heart J201435372541261925173339
   PubMed Web of Science ®Google Scholar
• IbanezBJamesSAgewallS2017ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)Eur Heart J2017
   PubMedGoogle Scholar
• GibsonCMMehranRBodeCPrevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCIN Engl J Med2016375252423243427959713
   PubMed Web of Science ®Google Scholar
• CannonCPGropperSBhattDLDesign and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With StentingClin Cardiol2016391055556427565018
   PubMed Web of Science ®Google Scholar
• HoshiTSatoANogamiAGoshoMAonumaKInvestigatorsSARationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary interventionJ Cardiol201769464865127443596
   PubMed Web of Science ®Google Scholar
• VranckxPLewalterTValgimigliMEvaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trialAm Heart J196105112
   PubMed Web of Science ®Google Scholar
• AshburnerJMGoASChangYInfluence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation StudyJ Am Geriatr Soc2017651354127861698
   PubMed Web of Science ®Google Scholar
• Beyer-WestendorfJForsterKEbertzFDrug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registryEuropace201517453053825694537
   PubMed Web of Science ®Google Scholar
• ManeshRPatelSTZhongYSicignanoNHopfKPeacockFMajor bleeding among rivaroxaban users with nonvalvular atrial fibrillation and diabetesPaper presented at: American College of CardiologyApril 2 2016Chicago
   Google Scholar
• LaubeESYuAGuptaDRivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active CancerAm J Cardiol2017120221321728549819
   PubMed Web of Science ®Google Scholar
• PrinsMHLensingAWBrightonTAOral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trialsLancet Haematol201411e37e4627030066
   PubMed Web of Science ®Google Scholar
• KronishIMYeSAdherence to cardiovascular medications: lessons learned and future directionsProg Cardiovasc Dis201355659060023621969
   PubMed Web of Science ®Google Scholar
• AmaraWAntoniouSBenefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillationEur Heart J Suppl201618Suppl DD1D628533706
   PubMed Web of Science ®Google Scholar
• AnJNiuFLangDTStroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical PracticeJ Am Heart Assoc201547
   PubMed Web of Science ®Google Scholar
• CotteFEBenhaddiHDuprat-LomonIVitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countriesClin Ther20143691160116825151574
   PubMed Web of Science ®Google Scholar
• SimonsLAOrtizMFreedmanSBWaterhouseBJColquhounDThomasGImproved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experienceCurr Med Res Opin201632111857186127463735
   PubMed Web of Science ®Google Scholar
• SorensenRJamie NielsenBLangtved PallisgaardJJi-Young LeeCTorp-PedersenCAdherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonistsEur Heart J Cardiovasc Pharmacother20173315115628158553
   PubMed Web of Science ®Google Scholar
• McHorneyCAPetersonEDLaliberteFComparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial FibrillationClin Ther201638112477248827789043
   PubMed Web of Science ®Google Scholar
• JackeviciusCATsadokMAEssebagVEarly non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillationHeart2017103171331133828286333
   PubMed Web of Science ®Google Scholar
• SchiavoniMMargaglioneMColucciaAUse of dabigatran and rivaroxaban in non-valvular atrial fibrillation: one-year follow-up experience in an Italian centreBlood Transfus20173116
   Google Scholar
• DavisTCWolfMSBassPF3rdLiteracy and misunderstanding prescription drug labelsAnn Intern Med20061451288789417135578
   PubMed Web of Science ®Google Scholar
• WolfMSCurtisLMWaiteKHelping patients simplify and safely use complex prescription regimensArch Intern Med2011171430030521357804
   PubMed Web of Science ®Google Scholar
• VrijensBHeidbuchelHNon-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherenceEuropace201517451452325694538
   PubMed Web of Science ®Google Scholar
• HanonOChaussadeEGuerangerPGrusonEBonanSGayAPatient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI StudyPloS One20161112e0166218
   Web of Science ®Google Scholar
• ColemanCIHaasSTurpieAGImpact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS SubstudyClin Cardiol2016391056556927362695
   PubMed Web of Science ®Google Scholar
• EngelbergerRPNollGSchmidtDInitiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) StudyEur J Int Med2015267508514
   PubMed Web of Science ®Google Scholar
• Marquez-ContrerasEMartell-ClarosNGil-GuillenVQuality of life with rivaroxaban in patients with non-valvular atrial fibrillation by therapeutic complianceQual Life Res201726364765428058574
   PubMed Web of Science ®Google Scholar